Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research report sent to investors on Monday morning. The brokerage issued a buy rating and a $103.00 price objective on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on the stock. Wedbush reaffirmed a buy rating and issued a $253.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, January 5th. Goldman Sachs Group downgraded shares of Intercept Pharmaceuticals from a neutral rating to a sell rating in a report on Wednesday, February 7th. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 16th. Laidlaw raised shares of Intercept Pharmaceuticals from a hold rating to a buy rating and set a $90.00 target price on the stock in a report on Wednesday, November 1st. Finally, Citigroup set a $74.00 target price on shares of Intercept Pharmaceuticals and gave the company a hold rating in a report on Thursday, December 21st. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $134.71.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) opened at $54.63 on Monday. The firm has a market cap of $1,360.78, a PE ratio of -3.69 and a beta of -2.13. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a fifty-two week low of $51.05 and a fifty-two week high of $135.59.

Hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its holdings in Intercept Pharmaceuticals by 48.2% during the third quarter. Legal & General Group Plc now owns 8,856 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,882 shares in the last quarter. Senvest Management LLC purchased a new stake in Intercept Pharmaceuticals during the third quarter worth about $33,883,000. Vanguard Group Inc. boosted its holdings in Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its holdings in Intercept Pharmaceuticals by 85.6% during the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 3,136 shares in the last quarter. Finally, Peregrine Capital Management LLC purchased a new stake in Intercept Pharmaceuticals during the fourth quarter worth about $7,055,000. 75.48% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://theolympiareport.com/2018/02/13/intercept-pharmaceuticals-icpt-coverage-initiated-at-deutsche-bank.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.